Rifamycin SV MMX

DRUG3 trials

Sponsors

Cosmo Technologies Ltd, RedHill Biopharma Limited, Hunter Holmes Mcguire Veteran Affairs Medical Center

Conditions

Cirrhosis, LiverHepatic EncephalopathyTraveler's Diarrhea

Phase 2

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

RedHill Biopharma LimitedTraveler's Diarrhea

Start: 2024-01-31End: 2025-12-31Target: 142Updated: 2023-01-27

Rifamycin in Minimal Hepatic Encephalopathy

CompletedNCT04082780

Hunter Holmes Mcguire Veteran Affairs Medical CenterCirrhosis, Liver, Hepatic Encephalopathy

Start: 2019-09-01End: 2023-04-28Updated: 2023-09-21

Phase 3

Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

CompletedNCT01142089

Cosmo Technologies LtdTraveler's Diarrhea

Start: 2010-05-27End: 2012-06-30Updated: 2018-06-08